Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or ($0.21) per...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that the waiting period under the...
Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) announced today that its annual meeting of stockholders scheduled for May 6, 2011 will be postponed indefinitely due to the recently...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the commencement of the tender offer for all outstanding shares of Inspire Pharmaceuticals...
The Law Offices of Vincent Wong are investigating the Board of Directors of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) for possible breaches of fiduciary duty and other...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Inspire Pharmaceuticals, Inc. (“Inspire” or...
Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Inspire Pharmaceuticals, Inc. (“Inspire” or the...
The Law Office of Abe Shainberg is investigating the Board of Directors of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) for possible breaches of fiduciary duty and other...
The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the securities...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
